Latest Information Update: 30 Mar 2007
At a glance
- Originator Molecular Targeting Technologies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 13 Nov 2001 This programme is available for licensing (http://www.mtarget.com/)
- 14 Jun 2001 New profile
- 14 Jun 2001 Preclinical development for Ischaemic heart disorders in USA (Unknown route)